Received Jun 29, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | Unknown | — |
The patient missed dose; Case reference number US-BN-2025-001371 is a spontaneous case initially received from pharmacist via Communication (reference number: USBAV25-1922) on 06-Aug-2025 and concerns a patient of an unknown age and gender. The patient's medical history and concomitant medication details were not provided. On an unknown date, the patient was vaccinated with the dose of RabAvert vaccine along with its reconstitution parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at an unknown dose, route or site of administration for unknown indication. On an unspecified date, the patient missed a dose (explicitly coded as 'missed dose'). At the time of initial report, it was unknown if the patient experienced any adverse event due to RabAvert. No further information was reported.; Reporter's Comments: A patient of an unknown age and gender missed a dose unknown time after vaccination with the dose of RabAvert vaccine along with its reconstitution parts: prefilled syringe, needle for injection and needle for reconstitution, at an unknown dose, route or site of administration for unknown indication. Product dose omission issue is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to RabAvert. The patient's medical history and concomitant medication details were not provided. Causality is not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A patient of an unknown age and gender missed a dose unknown time after vaccination with the dose of RabAvert vaccine along with its reconstitution parts: prefilled syringe, needle for injection and needle for reconstitution, at an unknown dose, route or site of administration for unknown indication. Product dose omission issue is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to RabAvert. The patient's medical history and concomitant medication details were not provided. Causality is not related to suspect product but to human factor. The case is non-serious.
Comments: None.